BK vs MXCT · P/E 17, rev $20.08B vs rev $38.6M
The Bank of New York Mellon Corporation (BK) versus MaxCyte Inc (MXCT) — a side-by-side from cached financials, not a winner call.
The Bank of New York Mellon Corporation (BK) is a banks - diversified company listed on US.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
Latest reported BK revenue for 2025-12-31 was $20.08B. Net income was $5.55B. Revenue was up 7.8% from 2024-12-31 to 2025-12-31. BK currently screens at market cap $94.14B and trailing P/E 17.0.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
BK currently screens at market cap $94.14B and trailing P/E 17.0. MXCT currently screens at market cap $124.3M.
Not investment advice. Open the BK and MXCT stock pages for the full models.
Not investment advice.